1. Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents
   Stephanie J. Franks et al, 2020, Materials Horizons CrossRef
2. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
   Meredith S. Eno et al, 2022, Journal of Medicinal Chemistry CrossRef
3. Targeting EGFR in Lung Cancer: Current Standards and Developments
   Asunción Díaz-Serrano et al, 2018, Drugs CrossRef
4. Effect of Wellness Education on Quality of Life of Patients With Non–Small Cell Lung Cancer Treated With First-Line Icotinib and on Their Family Caregivers
   Yanwei Li et al, 2019, Integrative Cancer Therapies CrossRef
5. Kinase-targeted cancer therapies: progress, challenges and future directions
   Khushwant S. Bhullar et al, 2018, Molecular Cancer CrossRef
6. Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors
   Qiang Shi et al, 2020, Expert Opinion on Drug Metabolism & Toxicology CrossRef
7. Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity
   Ysabella ZA Van Sebille et al, 2019, Experimental Biology and Medicine CrossRef
8. Dermatological Toxicities of Targeted Therapy
   Rahul Pansare et al, 2020, Handbook of Cancer Treatment-Related Symptons and Toxicities CrossRef
9. Introductory Chapter: Protein Kinases as Promising Targets for Drug Design against Cancer
   Rohit Bhatia et al, 2021, Protein Kinases - Promising Targets for Anticancer Drug Research CrossRef
10. A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non–Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies
    Lydia Chen et al, 2019, American Journal of Roentgenology CrossRef
11. Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation
    Hideaki Kageji et al, 2024, Bioorganic & Medicinal Chemistry Letters CrossRef
12. Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients
    Shuang Xin et al, 2020, The Pharmacogenomics Journal CrossRef
13. Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis
    Stephanie G. C. Kroeze et al, 2021, Cancers CrossRef
14. Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study
    Hirofumi Nagai et al, 2022, Journal of Pharmaceutical Health Care and Sciences CrossRef
15. Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan
    Yuichiro Ohe et al, 2020, Japanese Journal of Clinical Oncology CrossRef
16. A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids
    Daniela Rodrigues et al, 2022, International Journal of Molecular Sciences CrossRef
17. Design, synthesis and biological evaluation of novel tumor hypoxia-activated EGFR tyrosine kinase inhibitors
    Tingting Jia et al, 2022, Bioorganic Chemistry CrossRef
18. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy
    Yang‑Ling Li et al, 2018, Molecular Medicine Reports CrossRef
19. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
    Jing Huang et al, 2020, Scientific Reports CrossRef
20. Antitumor activity of alantolactone in lung cancer cell lines NCI‐H1299 and Anip973
    Jianli Liu et al, 2019, Journal of Food Biochemistry CrossRef